Tango’s PRMT5 inhibitor adds to daraxonrasib activity in pancreatic cancer

The strong response rate to Tango’s dual PRMT5 and KRAS inhibitor approach in pancreatic ductal adenocarcinoma is positioning the combination therapy for a pivotal trial, and building early support for the idea that complementary mechanisms could deepen antitumor activity beyond KRAS inhibition alone.

Tango Therapeutics Inc. (NASDAQ:TNGX) announced Monday that vopimetostat plus daraxonrasib produced a 92% objective response rate (ORR) and a 90% six-month progression-free survival (PFS) rate in 12 advanced pancreatic ductal adenocarcinoma (PDAC) patients with MTAP deletions and RAS mutations, in a Phase I/II trial. MTAP deletions occur in about 40% of patients and create sensitivity to PRMT5 inhibition...